IntroMedic Co., Ltd. announced that it expects to receive KRW 19.99999982 billion in funding from AMB 2000DC WON INC. and another investor
March 10, 2021
Share
IntroMedic Co., Ltd. (KOSDAQ:A150840) announced a private placement of 4,819,277 common shares of par value KRW 500 per share at a price of KRW 1,660 per share for gross proceeds of KRW 7,999,999,820 and series 12 unregistered coupon Non-guaranteed private convertible bonds for gross proceeds of KRW 12,000,000,000 on March 11, 2021. The transaction will include participation from Fort Hamilton Investment Fund for shares and AMB 2000DC WON INC. for bonds. The company will raise the funding through third party allocation. The bonds carry coupon rate of 5.5% and interest rate to maturity of 5.5%. The bonds maturity date is April 12, 2024. The bonds are fully convertible into 6,045,340 shares at a conversion price of KRW 1,985 per share. The conversion period starts on April 12, 2022 and ends March 12, 2024. The shares issued in the transaction are subject to a hold period of one year. The payment date is April 12, 2021. The transaction was approved by the board of directors of the company.
IntroMedic Co., Ltd. is a Korea-based company mainly engaged in the development, manufacture and distribution of medical equipment. The Companyâs products consist of capsule endoscope, which is used for small intestine check under the brand name MiroCam; disposable endoscope, which is used to detect abnormalities of the esophagus and the stomach under the brand name E.G. Scan, and other accessories, such as abdominal disposable data belts and others. The Company distributes its products within domestic market and to overseas markets.
INTROMEDIC CO., LTD. 
